728 x 90

FDA Approves Monthly Maintenance Dosing for Alzheimer’s Drug Leqembi

FDA Approves Monthly Maintenance Dosing for Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.

The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.

Ibtehaj Saleem
ADMINISTRATOR
PROFILE

Posts Carousel

Leave a Comment

Your email address will not be published. Required fields are marked with *

Latest Posts

Top Authors

Most Commented

Featured Videos